The objectives of the proposed work are (1) the development of a series of compounds capable of mobilizing aged cadmium deposits from the kidney, liver and other organs, (2) the determination of the conditions under which this must be carried out so that these organs can regain part or all of their normal functioning capacity and (3) the determination of the basic processes at the cellular level which are involved when cadmium mobilization occurs under the influence of our newly developed chelating agents. The biological parameters, determined in the studies listed below, will be used concurrently to develop structure-activity relationships which will serve as a guide for our efforts in the synthesis of new chelating agents for cadmium intoxication. The compounds which will mobilize aged cadmium deposits which we have developed during the past year (mostly dithiocarbamates with moderately polar substituents) as well as chelating agents which are to be newly synthesized will be used in a series of studies as follows. (a) Studies to determine how to mobilize aged cadmium deposits from the kidney so that kidney functioning returns to normal as the cadmium levels of the kidney are reduced. Kidney function will be followed by a determination of parameters indicative of cadmium induced kidney damage: urinary Beta2-microglobulin, urinary osmolarity, blood urea nitrogen values and related measures of such damage. (b) Comparative studies involving cell cultures, whole animals, and isolated metallothionein to obtain information on the basic cellular processes involved in the mobilization of aged cadmium deposits. These will use a variety of techniques i.e. standard cell culture techniques plus flow fluorocytometry, Cd n.m.r. studies on the cadmium transfer from metallothionein to chelating agent, as well as standard animal techniques. Pathological evaluations will be carried out as an integral part of the whole animal studies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES002638-06
Application #
3249949
Study Section
Toxicology Study Section (TOX)
Project Start
1981-07-01
Project End
1988-06-30
Budget Start
1986-07-01
Budget End
1987-06-30
Support Year
6
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
Schools of Arts and Sciences
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37203
Kostial, K; Blanusa, M; Piasek, M et al. (1999) Combined chelation therapy in reducing tissue lead concentrations in suckling rats. J Appl Toxicol 19:143-7
Singh, P K; Jones, M M; Lane, J E et al. (1997) Synthesis and in vitro trypanocidal activity of some novel iron chelating agents. Arzneimittelforschung 47:311-5
Kostial, K; Restek-Samarzija, N; Blanusa, M et al. (1997) Combined oral treatment with racemic and meso-2,3-dimercaptosuccinic acid for removal of mercury in rats. Pharmacol Toxicol 81:242-4
Jones, M M; Xu, C; Ladd, P A (1997) Selenite suppression of cadmium-induced testicular apoptosis. Toxicology 116:169-75
Jones, M M; Singh, P K; Kostial, K et al. (1997) Comparative in vivo lead mobilization of meso- and rac-2,3-dimercaptosuccinic acids in albino Wistar rats. Pharmacol Toxicol 80:182-6
Yan, H; Carter, C E; Xu, C et al. (1997) Cadmium-induced apoptosis in the urogenital organs of the male rat and its suppression by chelation. J Toxicol Environ Health 52:149-68
Kostial, K; Restek-Samarzija, N; Blanusa, M et al. (1997) Racemic-2,3-dimercaptosuccinic acid for inorganic mercury mobilization in rats. J Appl Toxicol 17:71-4
Xu, C; Johnson, J E; Singh, P K et al. (1996) In vivo studies of cadmium-induced apoptosis in testicular tissue of the rat and its modulation by a chelating agent. Toxicology 107:1-8
Jones, M M; Xu, C; Singh, P K et al. (1996) Cadmium mobilization by nitrogen donor chelating agents. J Toxicol Environ Health 48:71-80
Jones, M M; Singh, P K; Lane, J E et al. (1996) Inhibition of Trypanosoma cruzi epimastigotes in vitro by iron chelating agents. Arzneimittelforschung 46:1158-62

Showing the most recent 10 out of 79 publications